Historical toxicology data is often underused. Find out how Virtual Control Groups and AI could help researchers strengthen safety assessment while making better use of existing data.
Safety assessment is a fundamental part of drug development. Before a potential therapy reaches clinical trials, researchers need to understand its safety profile and identify potential toxicities. However, the demands placed on toxicology are changing.
Drug developers are expected to deliver programmes more quickly, improve the relevance of nonclinical findings to humans and reduce reliance on in vivo studies. Advances in artificial intelligence (AI), digital platforms and data science are also creating new opportunities to rethink how safety studies are designed and interpreted.
One development attracting attention is the use of Virtual Control Groups (VCGs), which use carefully curated historical control data to replace, reduce or augment concurrent control groups in selected toxicology studies.
Drug Target Review spoke with Laura Lotfi, Digital Scientific Innovation and Product Management Leader at Charles River Laboratories, about the challenges facing modern safety assessment, the growing role of advanced analytics and why making better use of existing data could change how toxicology is conducted.
Already a member? Sign in